Existing antibody molecules are converted in proprietary AbAccel™ libraries and screened for variants with optimized affinities and biophysical properties
Proprietary AbAccel™ libraries are cloned for existing lead candidates and screened for variants with optimized affinities and biophysical properties. AbAccel™ has identified optimized antibody candidates that demonstrated a more than 100-fold improved affinity, while preserving other properties such as species cross-reactivity, specificity and stability.
Lead optimization with AbAccel™ is based on a proprietary algorithm. HCDR3 regions of lead candidates are identified and transferred to a compatible VH/VL framework pair with proven performance for GMP production.